Press Releases

Date Title and Summary Additional Formats
Toggle Summary After Much Anticipation, Cellectar Biosciences Initiates NCI-Supported Phase II Trial of CLR 131 in Multiple Myeloma and Other Blood Cancers
MADISON, Wis., March 30, 2017 (GLOBE NEWSWIRE) -- Madison, Wis. Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused clinical stage biotechnology company, today announces the initiation of a Phase II clinical study of its lead phospholipid drug conjugate (PDC) CLR 131 in patients with
View HTML
Toggle Summary Cellectar Announces 1-for-10 Reverse Stock Split
MADISON, Wis. , July 13, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, announces a 1-for-10 reverse split of its common stock, effective at
View HTML
Toggle Summary Cellectar Announces Expansion of Diffuse Large B-Cell Lymphoma Cohort in CLR 131 Phase 2 Trial
Response rate in cohort exceeded pre-specified value MADISON, Wis. , June 28, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announces
View HTML
Toggle Summary Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort in Phase 2 Trial of CLR 131
Multiple myeloma cohort exceeded pre-specified criteria for clinically meaningful benefit
View HTML
Toggle Summary Cellectar Announces Initiation of Phase II Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
  Cellectar Expects Results from this 36-Patient, Multi-Center Imaging Trial by Year-End 2014 MADISON, Wis., March 04, 2014, – Cellectar Biosciences, Inc. (OTCQX: CLRB) a biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced enrollment of the
View HTML
Toggle Summary Cellectar Announces Issuance of U.S. Patent Covering CLR 131 Use in Multiple Myeloma
MADISON, Wis. , April 03, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, announces that the United States Patent and Trademark Office
View HTML
Toggle Summary Cellectar Announces Late-Breaking Poster Presentations at AACR 2018 Featuring PDCs and CLR 131
MADISON, Wis. , March 15, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces that results from two preclinical studies highlighting the
View HTML
Toggle Summary Cellectar Announces Updated Median Overall Survival of 26.2 Months from Cohort 1 of CLR 131 Phase 1 Trial in Advanced Multiple Myeloma
MADISON, Wis., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the "company"), today announces that the ongoing median overall survival (mOS) from Cohort 1 of the Phase 1 study of its lead PDC™ compound, CLR 131
View HTML
Toggle Summary Cellectar Appoints Industry Veteran Jim Caruso President and Chief Executive Officer
Dr. Simon Pedder to Retire
View HTML
Toggle Summary Cellectar Biosciences Adds Industry Veterans Douglas Swirsky and Frederick Driscoll to Its Board of Directors
MADISON, Wis., April 10, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused clinical stage biotechnology company, today announces it has appointed Douglas J. Swirsky and Frederick W. Driscoll to its board of directors.
View HTML